JP2017038592A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017038592A5 JP2017038592A5 JP2016140458A JP2016140458A JP2017038592A5 JP 2017038592 A5 JP2017038592 A5 JP 2017038592A5 JP 2016140458 A JP2016140458 A JP 2016140458A JP 2016140458 A JP2016140458 A JP 2016140458A JP 2017038592 A5 JP2017038592 A5 JP 2017038592A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- amino acid
- seq
- acid sequence
- represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical group 0.000 claims 21
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 18
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 18
- 102000009389 Prostaglandin D receptors Human genes 0.000 claims 17
- 108050000258 Prostaglandin D receptors Proteins 0.000 claims 17
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 11
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 5
- 235000003704 aspartic acid Nutrition 0.000 claims 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 5
- 239000004475 Arginine Substances 0.000 claims 4
- 239000004471 Glycine Substances 0.000 claims 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 4
- 239000004473 Threonine Substances 0.000 claims 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 4
- 229960000310 isoleucine Drugs 0.000 claims 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 4
- 229930182817 methionine Natural products 0.000 claims 4
- 230000004048 modification Effects 0.000 claims 4
- 238000012986 modification Methods 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 4
- 239000004474 valine Substances 0.000 claims 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 3
- 235000009582 asparagine Nutrition 0.000 claims 3
- 229960001230 asparagine Drugs 0.000 claims 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- 210000004241 Th2 cell Anatomy 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 235000004279 alanine Nutrition 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- 210000004408 hybridoma Anatomy 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 230000009257 reactivity Effects 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 241000282693 Cercopithecidae Species 0.000 claims 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- 206010014950 Eosinophilia Diseases 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 210000000447 Th1 cell Anatomy 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 210000003651 basophil Anatomy 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015141633 | 2015-07-15 | ||
| JP2015141633 | 2015-07-15 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018044483A Division JP2018138546A (ja) | 2015-07-15 | 2018-03-12 | ヒトｃｒｔｈ２に特異的に結合する抗体を含む組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017038592A JP2017038592A (ja) | 2017-02-23 |
| JP2017038592A5 true JP2017038592A5 (enExample) | 2018-02-08 |
| JP6309050B2 JP6309050B2 (ja) | 2018-04-11 |
Family
ID=57757419
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016140458A Expired - Fee Related JP6309050B2 (ja) | 2015-07-15 | 2016-07-15 | ヒトｃｒｔｈ２に特異的に結合する抗体 |
| JP2018044483A Pending JP2018138546A (ja) | 2015-07-15 | 2018-03-12 | ヒトｃｒｔｈ２に特異的に結合する抗体を含む組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018044483A Pending JP2018138546A (ja) | 2015-07-15 | 2018-03-12 | ヒトｃｒｔｈ２に特異的に結合する抗体を含む組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US9938349B2 (enExample) |
| EP (1) | EP3323832A4 (enExample) |
| JP (2) | JP6309050B2 (enExample) |
| KR (1) | KR20180030030A (enExample) |
| CN (1) | CN107849139B (enExample) |
| AU (1) | AU2016293807B2 (enExample) |
| CA (1) | CA2992262A1 (enExample) |
| HK (1) | HK1255839A1 (enExample) |
| TW (1) | TWI726897B (enExample) |
| WO (1) | WO2017010567A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105307641A (zh) | 2013-05-03 | 2016-02-03 | 西莱克塔生物科技公司 | 用于降低不期望体液免疫应答的给药组合 |
| ES3052981T3 (en) | 2017-01-24 | 2026-01-16 | Kyowa Kirin Co Ltd | Therapeutic or prophylactic agent for treating radiation damage |
| EP4599848A3 (en) | 2017-03-11 | 2025-12-03 | Cartesian Therapeutics, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| CN107779500A (zh) * | 2017-10-25 | 2018-03-09 | 上海药明生物技术有限公司 | 一种快速获取大鼠杂交瘤细胞单克隆抗体序列的测序方法及引物序列 |
| WO2019169015A1 (en) * | 2018-02-27 | 2019-09-06 | Equillium, Inc. | Anti cd6 antibodies for treating severe asthma |
| KR102991359B1 (ko) * | 2018-12-28 | 2026-07-16 | 쿄와 기린 가부시키가이샤 | TfR에 결합하는 이중 특이적 항체 |
| US12553041B2 (en) | 2019-06-04 | 2026-02-17 | Cartesian Therapeutics Inc. | Formulations and doses of pegylated uricase |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69734141T2 (de) * | 1996-06-05 | 2006-07-13 | Bml Inc. | PROTEIN, DAS FÜR MENSCHLICHE Th2-ZELLEN SPEZIFISCH IST, DAFÜR KODIERENDES GEN UND KORRESPONDIERENDE TRANSFORMANTE, REKOMBINANTER VEKTOR UND MONOKLONALER ANTKÖRPER |
| WO2005093092A2 (en) * | 2004-03-26 | 2005-10-06 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44) |
| BR112015021521A2 (pt) * | 2013-03-15 | 2017-10-10 | Genentech Inc | anticorpos anti-crth2 e métodos para seu uso |
-
2016
- 2016-07-15 TW TW105122490A patent/TWI726897B/zh not_active IP Right Cessation
- 2016-07-15 AU AU2016293807A patent/AU2016293807B2/en not_active Ceased
- 2016-07-15 JP JP2016140458A patent/JP6309050B2/ja not_active Expired - Fee Related
- 2016-07-15 CA CA2992262A patent/CA2992262A1/en active Pending
- 2016-07-15 EP EP16824547.0A patent/EP3323832A4/en not_active Withdrawn
- 2016-07-15 HK HK18114915.3A patent/HK1255839A1/en unknown
- 2016-07-15 KR KR1020187000812A patent/KR20180030030A/ko not_active Ceased
- 2016-07-15 CN CN201680041608.6A patent/CN107849139B/zh not_active Expired - Fee Related
- 2016-07-15 WO PCT/JP2016/071027 patent/WO2017010567A1/ja not_active Ceased
- 2016-11-03 US US15/342,534 patent/US9938349B2/en not_active Expired - Fee Related
-
2018
- 2018-02-16 US US15/932,185 patent/US10100120B2/en active Active
- 2018-03-12 JP JP2018044483A patent/JP2018138546A/ja active Pending
- 2018-09-07 US US16/124,706 patent/US20180371100A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7508425B2 (ja) | シグナル調節タンパク質αに対する抗体及び使用方法 | |
| JP7230090B2 (ja) | 抗ｐｄ－１抗体及びその使用方法 | |
| CN108883173B (zh) | 抗体和其使用方法 | |
| CN101512008A (zh) | 白介素-13结合蛋白 | |
| WO2018089628A1 (en) | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof | |
| JP6466904B2 (ja) | インターフェロンアルファ及びオメガ抗体アンタゴニスト | |
| KR20180015650A (ko) | 항-ox40 항체 및 이의 사용 방법 | |
| JP2015506912A5 (enExample) | ||
| JP7842914B2 (ja) | Ｃ５ａＲを標的とする抗体 | |
| JP2017523805A5 (enExample) | ||
| JP2025542239A (ja) | 自己免疫疾患の治療 | |
| KR102965375B1 (ko) | 이중특이적 항-ccl2 항체 | |
| JP2026506716A (ja) | Ｉｌ－３６ｒ結合タンパク質及びその医薬的使用 | |
| CN118159562A (zh) | 靶向ccr2的抗体 | |
| HK40109063A (en) | Anti-lag-3 antibodies and methods of use thereof | |
| HK40033147B (en) | Anti-tigit antibodies, preparation methods and use thereof | |
| EA041979B1 (ru) | Антитела против pd-1 и способы их применения |